CCNB1: A Potential Drug Target and Biomarker for G2-Specific Cyclin-B1 (ISO Form 1)
CCNB1: A Potential Drug Target and Biomarker for G2-Specific Cyclin-B1 (ISO Form 1)
G2-specific cyclin-B1 (ISO Form 1) is a key regulator of cell cycle progression and has been implicated in various cellular processes, including cell growth, apoptosis, and fertility. The G2 phase is a critical stage in the cell cycle where the cell prepares for cell division by producing duplicated chromosomes in preparation for the subsequent meiosis. G2-specific cyclin-B1 plays a crucial role in regulating the timing and quality of chromatin replication, as well as the proper execution of cell division.
G2-specific cyclin-B1 is a protein that consists of 183 amino acids and has a calculated molecular weight of 19.1 kDa. It is a member of the cyclin family, which includes several other proteins involved in regulating the cell cycle, including cyclin A, cyclin D1, and cyclin E. G2-specific cyclin-B1 is specifically expressed in the germ cells, where it plays a vital role in regulating meiosis.
Recent studies have identified G2-specific cyclin-B1 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and reproductive disorders. In this article, we will explore the potential of G2-specific cyclin-B1 as a drug target and biomarker, as well as its underlying mechanism of action.
Potential Drug Target and Biomarker
G2-specific cyclin-B1 has been identified as a potential drug target due to its involvement in various cellular processes that are crucial for human health and disease. One of the primary targets of G2-specific cyclin-B1 is the regulation of cell division. G2-specific cyclin-B1 is known to play a role in regulating the timing and quality of chromatin replication, which is essential for the proper execution of cell division.
In addition to its role in cell division, G2-specific cyclin-B1 has also been shown to be involved in various signaling pathways that are important for human health and disease. For example, G2-specific cyclin-B1 has been shown to be involved in the regulation of cell apoptosis, which is a critical mechanism that helps remove damaged or dysfunctional cells from the body.
G2-specific cyclin-B1 has also been shown to play a role in the regulation of fertility and reproductive disorders. For example, G2-specific cyclin-B1 has been shown to play a role in the regulation of meiosis, which is the process by which a cell divides. In addition, G2-specific cyclin-B1 has also been shown to play a role in the regulation of chromosomal stability, which is essential for proper fetal development and fertility.
Underlying Mechanism of Action
The underlying mechanism of action of G2-specific cyclin-B1 is based on its ability to regulate the timing and quality of chromatin replication. G2-specific cyclin-B1 is a key regulator of the G2 phase of the cell cycle, which is the stage of cell growth and preparation for cell division. During the G2 phase, G2-specific cyclin-B1 plays a critical role in regulating the timing and quality of chromatin replication, which is essential for the proper execution of cell division.
G2-specific cyclin-B1 uses a unique mechanism to regulate chromatin replication. G2-specific cyclin-B1 binds to the centromere region of chromosome 2, which is the region of the chromosome that is responsible for proper attachment and separation during
Protein Name: Cyclin B1
Functions: Essential for the control of the cell cycle at the G2/M (mitosis) transition
The "CCNB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCNB1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CCNB1IP1 | CCNB2 | CCNB2P1 | CCNB3 | CCNC | CCND1 | CCND2 | CCND2-AS1 | CCND3 | CCNDBP1 | CCNE1 | CCNE2 | CCNF | CCNG1 | CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247
